1. Home
  2. CW vs BIIB Comparison

CW vs BIIB Comparison

Compare CW & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Curtiss-Wright Corporation

CW

Curtiss-Wright Corporation

HOLD

Current Price

$545.79

Market Cap

21.3B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.61

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CW
BIIB
Founded
1929
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.3B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
CW
BIIB
Price
$545.79
$181.61
Analyst Decision
Buy
Buy
Analyst Count
6
23
Target Price
$534.00
$176.48
AVG Volume (30 Days)
240.0K
1.9M
Earning Date
11-05-2025
10-30-2025
Dividend Yield
0.18%
N/A
EPS Growth
15.99
N/A
EPS
12.27
10.97
Revenue
$3,375,704,000.00
$10,065,900,000.00
Revenue This Year
$13.58
$3.61
Revenue Next Year
$7.17
N/A
P/E Ratio
$44.37
$16.52
Revenue Growth
9.51
4.77
52 Week Low
$266.88
$110.04
52 Week High
$612.28
$185.17

Technical Indicators

Market Signals
Indicator
CW
BIIB
Relative Strength Index (RSI) 45.76 72.92
Support Level $528.92 $174.53
Resistance Level $556.87 $182.94
Average True Range (ATR) 17.89 5.22
MACD -1.27 0.25
Stochastic Oscillator 41.36 83.54

Price Performance

Historical Comparison
CW
BIIB

About CW Curtiss-Wright Corporation

Curtiss-Wright Corporation delivers engineered products and services to commercial, defence, power generation, and other industrial markets. It offers industrial vehicle components, control systems, weapons handling systems, pumps, valves, and other solutions. The company has three reportable segments based on the markets serviced: Naval & Power, which provides coolant pumps, power-dense compact motors, generators, secondary propulsion systems, pumps, pump seals, valves, control rod drive mechanisms, and fastening systems that also generate maximum revenue for the company; Its others segments are Aerospace & Industrial and Defense Electronics. Geographically, the company generates its key revenue from the United States of America, followed by the United Kingdom and other countries.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: